BCM
BCLI

Blume Capital Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Blume Capital Management’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-4
Closed – – 290
2014
Q4 		$0 Buy
+4
New +$210 ﹤0.01% 293

Other funds holding BCLI

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
M&T Bank
M&T Bank Buffalo, New York $29.2B AUM 22.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Blume Capital Management's BCLI Position: Q1 2015 in Review

Blume Capital Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q1 2015, closing a stake of 4 shares.

Blume Capital Management first reported a position in BCLI in Q4 2014 and held it in 1 quarter. The position peaked at $0 in Q4 2014. 21 funds tracked by Wall St. Rank hold BCLI as of Q1 2015.

  • Blume Capital Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q1 2015 after selling out during the quarter.
  • Blume Capital Management sold 4 BRAINSTORM CELL THERAPUTC shares in Q1 2015.
  • Blume Capital Management first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2014 and held it in 1 quarter.
  • Blume Capital Management's BRAINSTORM CELL THERAPUTC position peaked at $0 in Q4 2014.
  • 21 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q1 2015.

Based on Blume Capital Management's 13F filing for Q1 2015, filed 5 May 2015.